KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075
Debt
Debt-to-Equity RatioN/A
Current Ratio2.73
Quick Ratio2.73
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.50 million
Price / Sales64.66
Cash FlowN/A
Price / CashN/A
Book Value$3.22 per share
Price / Book2.79
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-18,600,000.00
Net Margins-527.53%
Return on Equity-65.77%
Return on Assets-46.48%
Miscellaneous
Employees28
Outstanding Shares10,800,000
Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions
What is Kalvista Pharmaceuticals' stock symbol?
Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were Kalvista Pharmaceuticals' earnings last quarter?
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) posted its earnings results on Thursday, December, 14th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.05. The specialty pharmaceutical company had revenue of $1.13 million for the quarter. Kalvista Pharmaceuticals had a negative return on equity of 65.77% and a negative net margin of 527.53%. View Kalvista Pharmaceuticals' Earnings History.
When is Kalvista Pharmaceuticals' next earnings date?
What price target have analysts set for KALV?
1 equities research analysts have issued 12 month target prices for Kalvista Pharmaceuticals' shares. Their predictions range from $27.00 to $27.00. On average, they expect Kalvista Pharmaceuticals' stock price to reach $27.00 in the next twelve months. View Analyst Ratings for Kalvista Pharmaceuticals.
Who are some of Kalvista Pharmaceuticals' key competitors?
Some companies that are related to Kalvista Pharmaceuticals include Seres Therapeutics (MCRB), Corvus Pharmaceuticals (CRVS), MediciNova (MNOV), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Syros Pharmaceuticals (SYRS), Kala Pharmaceuticals (KALA), Paratek Pharmaceuticals (PRTK), Innate Pharma (IPHYF), Minerva Neurosciences (NERV), Corbus Pharmaceuticals (CRBP), Clearside Biomedical (CLSD), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX) and Sienna Biopharmaceuticals (SNNA).
Who are Kalvista Pharmaceuticals' key executives?
Kalvista Pharmaceuticals' management team includes the folowing people:
- Mr. Thomas Andrew Crockett M.B.A., CEO & Director (Age 43)
- Mr. Benjamin L. Palleiko, Chief Financial Officer (Age 52)
- Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 55)
- Mr. John B. McKune, VP of Fin. (Age 42)
- Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 58)
Has Kalvista Pharmaceuticals been receiving favorable news coverage?
Press coverage about KALV stock has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kalvista Pharmaceuticals earned a news impact score of 0.08 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.49 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Kalvista Pharmaceuticals' major shareholders?
Kalvista Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (8.33%), Millennium Management LLC (2.12%), Stanley Laman Group Ltd. (0.42%) and JPMorgan Chase & Co. (0.19%). Company insiders that own Kalvista Pharmaceuticals stock include Holdings A/S Novo and Rajeev M Shah. View Institutional Ownership Trends for Kalvista Pharmaceuticals.
Which institutional investors are selling Kalvista Pharmaceuticals stock?
Which institutional investors are buying Kalvista Pharmaceuticals stock?
How do I buy shares of Kalvista Pharmaceuticals?
Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kalvista Pharmaceuticals' stock price today?
One share of KALV stock can currently be purchased for approximately $8.98.
How big of a company is Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals has a market capitalization of $92.09 million and generates $1.50 million in revenue each year. Kalvista Pharmaceuticals employs 28 workers across the globe.
How can I contact Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]
MarketBeat Community Rating for Kalvista Pharmaceuticals (KALV)
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
